NASDAQ:AKU

Akumin Competitors

$3.06
-0.09 (-2.86 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.06
$3.18
50-Day Range
$2.96
$3.80
52-Week Range
$1.69
$4.10
Volume13,165 shs
Average Volume134,416 shs
Market Capitalization$217.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Akumin (NASDAQ:AKU) Vs. PSNL, PHAR, PCVX, VRAY, EPZM, and GTHX

Should you be buying AKU stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Akumin, including Personalis (PSNL), Pharming Group (PHAR), Vaxcyte (PCVX), ViewRay (VRAY), Epizyme (EPZM), and G1 Therapeutics (GTHX).

Personalis (NASDAQ:PSNL) and Akumin (NASDAQ:AKU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Personalis and Akumin's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Personalis$65.21 million13.13$-25,080,000.00($1.39)-14.03
AkuminN/AN/AN/AN/AN/A

Akumin has lower revenue, but higher earnings than Personalis.

Insider and Institutional Ownership

65.5% of Personalis shares are owned by institutional investors. Comparatively, 30.4% of Akumin shares are owned by institutional investors. 8.2% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Personalis and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Personalis-45.13%-27.53%-19.66%
AkuminN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Personalis and Akumin, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Personalis01802.89
Akumin00103.00

Personalis presently has a consensus target price of $40.1111, suggesting a potential upside of 105.70%. Given Personalis' higher possible upside, research analysts clearly believe Personalis is more favorable than Akumin.

Summary

Personalis beats Akumin on 5 of the 9 factors compared between the two stocks.

Pharming Group (NASDAQ:PHAR) and Akumin (NASDAQ:AKU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

30.4% of Akumin shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pharming Group and Akumin, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharming Group0000N/A
Akumin00103.00

Earnings & Valuation

This table compares Pharming Group and Akumin's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharming GroupN/AN/AN/AN/AN/A
AkuminN/AN/AN/AN/AN/A

Profitability

This table compares Pharming Group and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharming GroupN/AN/AN/A
AkuminN/AN/AN/A

Summary

Akumin beats Pharming Group on 2 of the 2 factors compared between the two stocks.

Akumin (NASDAQ:AKU) and Vaxcyte (NASDAQ:PCVX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

30.4% of Akumin shares are held by institutional investors. Comparatively, 74.1% of Vaxcyte shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Akumin and Vaxcyte, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akumin00103.00
Vaxcyte00403.00

Vaxcyte has a consensus target price of $48.00, suggesting a potential upside of 191.79%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Akumin.

Earnings and Valuation

This table compares Akumin and Vaxcyte's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkuminN/AN/AN/AN/AN/A
VaxcyteN/AN/A$-50,270,000.00N/AN/A

Profitability

This table compares Akumin and Vaxcyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkuminN/AN/AN/A
VaxcyteN/AN/AN/A

Summary

Vaxcyte beats Akumin on 3 of the 3 factors compared between the two stocks.

Akumin (NASDAQ:AKU) and ViewRay (NASDAQ:VRAY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

30.4% of Akumin shares are held by institutional investors. Comparatively, 83.0% of ViewRay shares are held by institutional investors. 15.5% of ViewRay shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Akumin and ViewRay, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akumin00103.00
ViewRay10602.71

ViewRay has a consensus target price of $4.8571, suggesting a potential downside of 6.41%. Given ViewRay's higher possible upside, analysts plainly believe ViewRay is more favorable than Akumin.

Earnings and Valuation

This table compares Akumin and ViewRay's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkuminN/AN/AN/AN/AN/A
ViewRay$87.78 million9.56$-120,200,000.00($1.18)-4.40

Akumin has higher earnings, but lower revenue than ViewRay.

Profitability

This table compares Akumin and ViewRay's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkuminN/AN/AN/A
ViewRay-166.74%-63.41%-36.34%

Summary

ViewRay beats Akumin on 5 of the 9 factors compared between the two stocks.

Akumin (NASDAQ:AKU) and Epizyme (NASDAQ:EPZM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

30.4% of Akumin shares are held by institutional investors. Comparatively, 89.8% of Epizyme shares are held by institutional investors. 16.3% of Epizyme shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Akumin and Epizyme, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akumin00103.00
Epizyme02402.67

Epizyme has a consensus target price of $16.3333, suggesting a potential upside of 98.94%. Given Epizyme's higher possible upside, analysts plainly believe Epizyme is more favorable than Akumin.

Earnings and Valuation

This table compares Akumin and Epizyme's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkuminN/AN/AN/AN/AN/A
Epizyme$23.80 million35.18$-170,290,000.00($1.93)-4.25

Akumin has higher earnings, but lower revenue than Epizyme.

Profitability

This table compares Akumin and Epizyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkuminN/AN/AN/A
Epizyme-1,899.35%-83.45%-52.66%

Summary

Epizyme beats Akumin on 5 of the 9 factors compared between the two stocks.

Akumin (NASDAQ:AKU) and G1 Therapeutics (NASDAQ:GTHX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider & Institutional Ownership

30.4% of Akumin shares are held by institutional investors. Comparatively, 77.9% of G1 Therapeutics shares are held by institutional investors. 14.5% of G1 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Akumin and G1 Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akumin00103.00
G1 Therapeutics00703.00

G1 Therapeutics has a consensus target price of $49.1667, suggesting a potential upside of 149.07%. Given G1 Therapeutics' higher possible upside, analysts plainly believe G1 Therapeutics is more favorable than Akumin.

Earnings and Valuation

This table compares Akumin and G1 Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkuminN/AN/AN/AN/AN/A
G1 TherapeuticsN/AN/A$-122,450,000.00($3.27)-6.04

Profitability

This table compares Akumin and G1 Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkuminN/AN/AN/A
G1 TherapeuticsN/A-49.35%-41.53%

Summary

G1 Therapeutics beats Akumin on 4 of the 6 factors compared between the two stocks.


Akumin Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Personalis logo
PSNL
Personalis
1.6$19.50-16.7%$856.21 million$65.21 million-18.40Earnings Announcement
Analyst Revision
Gap Down
Pharming Group logo
PHAR
Pharming Group
0.0$13.20-0.0%$846.50 millionN/A0.00
Vaxcyte logo
PCVX
Vaxcyte
1.7$16.45-7.2%$844.79 millionN/A0.00Gap Up
ViewRay logo
VRAY
ViewRay
1.3$5.19-4.8%$839.43 million$87.78 million-5.83Earnings Announcement
Epizyme logo
EPZM
Epizyme
1.9$8.21-1.0%$837.22 million$23.80 million-3.68Earnings Announcement
Analyst Revision
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$19.74-4.4%$830.23 millionN/A-6.81Earnings Announcement
Analyst Revision
News Coverage
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.31-4.4%$825.55 million$459.95 million35.26
Vor Biopharma logo
VOR
Vor Biopharma
1.6$22.19-10.5%$823.87 millionN/A0.00
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$22.44-6.4%$823.46 millionN/A0.00Earnings Announcement
So-Young International logo
SY
So-Young International
1.1$7.53-16.9%$814.55 million$165.42 million188.25Upcoming Earnings
High Trading Volume
News Coverage
Gap Down
Nkarta logo
NKTX
Nkarta
1.8$24.51-12.9%$805.67 millionN/A0.00Analyst Report
Merus logo
MRUS
Merus
1.8$20.92-2.9%$802.28 million$31.13 million-6.81Earnings Announcement
Analyst Report
FDMT
4D Molecular Therapeutics
1.3$30.01-9.3%$801.09 millionN/A0.00News Coverage
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$18.51-10.5%$798.61 million$253.67 million17.14Earnings Announcement
Analyst Report
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$21.94-4.1%$797.04 millionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$16.82-4.1%$788.69 million$69.89 million-4.01Earnings Announcement
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.31-3.5%$783.06 millionN/A0.00Upcoming Earnings
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$20.52-3.3%$776.01 millionN/A0.00
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.6$21.99-4.6%$774.14 million$296.70 million44.88Earnings Announcement
Vaxart logo
VXRT
Vaxart
1.3$6.54-10.1%$771.49 million$9.86 million-11.08Insider Selling
ChemoCentryx logo
CCXI
ChemoCentryx
1.7$10.97-4.6%$765.16 million$36.13 million-16.37Insider Buying
Gap Up
The Joint logo
JYNT
The Joint
1.3$53.48-0.8%$762.46 million$48.45 million198.08Earnings Announcement
Analyst Report
Anavex Life Sciences logo
AVXL
Anavex Life Sciences
1.3$10.87-4.0%$761.24 millionN/A-24.16Upcoming Earnings
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$28.91-10.0%$760.91 million$20.79 million-9.97News Coverage
Gap Down
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.8$15.64-2.6%$754.41 million$1.52 million-8.32
Surmodics logo
SRDX
Surmodics
1.5$54.16-1.9%$751.09 million$94.86 million677.00
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.4$30.40-0.4%$748.81 millionN/A-9.02
OrganiGram logo
OGI
OrganiGram
1.6$2.51-9.6%$748.56 million$64.61 million-3.69
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$18.16-1.9%$743.89 million$6.83 million-18.72
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.4$10.98-4.7%$738.00 millionN/A0.00News Coverage
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.4$4.72-1.3%$733.82 million$1.12 million-4.77Earnings Announcement
Gap Up
RFL
Rafael
0.0$44.00-5.9%$733.57 million$4.91 million-67.69
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$18.97-8.1%$723.46 millionN/A-7.84Upcoming Earnings
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$30.85-2.9%$712.33 million$13.80 million-14.90Earnings Announcement
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.5$22.26-1.7%$708.76 millionN/A0.00
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$21.81-2.8%$706.88 million$5.78 million-10.24Earnings Announcement
Analyst Report
Analyst Revision
Annexon logo
ANNX
Annexon
1.9$18.48-7.8%$706.68 millionN/A0.00
AnaptysBio logo
ANAB
AnaptysBio
1.5$25.73-1.7%$704.20 million$8 million-9.49
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$9.73-1.3%$700.04 million$154.60 million-42.30Earnings Announcement
Analyst Revision
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.68-1.3%$691.20 million$19.56 million-19.91Upcoming Earnings
Chimerix logo
CMRX
Chimerix
1.7$8.01-1.7%$690.55 million$12.52 million-14.05Earnings Announcement
SeaSpine logo
SPNE
SeaSpine
1.5$20.81-2.4%$690.08 million$159.08 million-12.46Analyst Report
Athira Pharma logo
ATHA
Athira Pharma
1.7$18.57-0.5%$689.32 millionN/A0.00
DBV Technologies logo
DBVT
DBV Technologies
1.1$6.22-4.0%$683.41 million$14.75 million-2.67Gap Down
AKYA
Akoya BioSciences
0.0$19.13-3.2%$682.73 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.3$15.00-8.7%$681.83 million$22.99 million-7.98Earnings Announcement
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.64-5.3%$671.08 million$2.22 million-15.53Upcoming Earnings
Agenus logo
AGEN
Agenus
1.6$3.01-2.0%$669.55 million$150.05 million-2.76Earnings Announcement
Analyst Revision
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$15.43-5.4%$653.97 million$17.26 million-4.29
Ardelyx logo
ARDX
Ardelyx
1.6$6.55-2.9%$646.41 million$5.28 million-6.49Earnings Announcement
Analyst Revision
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.